Table S2.
Predictors of 1 log10 decline in viremia at 3- or 6-mo postpartum
| Viral load decline: Third trimester to 3 mo postpartum | Viral load decline: Third trimester to 6 mo postpartum | |||||||||
| <1 log10 IU/mL | ≥1 log10 IU/mL | <1 log10 IU/mL | ≥1 log10 IU/mL | |||||||
| Variable | n | Median (IQR) | n | Median (IQR) | P | n | Median (IQR) | n | Median (IQR) | P |
| Maternal age at delivery (y) | 21 | 26.6 (24.7, 30) | 13 | 27.2 (25.6, 30.1) | 0.625 | 12 | 26.2 (24, 30.2) | 14 | 26.5 (25.4, 30) | 0.631 |
| Estimated duration of HCV infection | 19 | 3.7 (1.8, 11.2) | 12 | 1.5 (1.1, 5.7) | 0.108 | 12 | 3 (1.8, 5.7) | 12 | 1.9 (1.5, 8.7) | 0.660 |
| Gravida | 21 | 4 (3, 5) | 13 | 3 (2.5, 4.5) | 0.578 | 12 | 3 (2.3, 4.8) | 14 | 3.5 (2.8, 5) | 0.619 |
| Pregnancy gestation (wk) | 21 | 38.9 (36.6, 39.5) | 13 | 39 (38.1, 39.3) | 0.581 | 12 | 38.9 (36.4, 39.9) | 14 | 39.1 (38.2, 39.5) | 0.752 |
| HCV viral load (log10 IU/mL) | ||||||||||
| Third trimester | 21 | 5.8 (5.5, 6.8) | 13 | 6.0 (5.5, 7.0) | 0.807 | 12 | 6.1 (5.4, 6.6) | 14 | 6.4 (5.7, 7) | 0.322 |
| ALT (U/L) | ||||||||||
| Third trimester | 21 | 29.5 (21.5, 45.8) | 13 | 30 (14, 52.5) | 0.814 | 12 | 33.5 (20.8, 46.8) | 14 | 29.5 (17, 61.4) | 0.990 |
| 3-mo postpartum | 21 | 80 (55.5, 147) | 13 | 37 (21.5, 107) | 0.056 | 12 | 95 (57.3, 237) | 14 | 61.5 (23.8, 103) | 0.078 |
| 6-mo postpartum | 15 | 84 (26, 114) | 11 | 33 (23, 112) | 0.356 | 12 | 93.5 (25.3, 116) | 14 | 36 (23, 91) | 0.494 |
| ELISpot magnitude (EM) | ||||||||||
| Third trimester | 21 | 50 (0, 173.8) | 11 | 70 (0, 325) | 0.502 | 12 | 83.8 (0, 190) | 12 | 113.1 (0, 324) | 0.545 |
| 3-mo postpartum | 17 | 127.5 (0, 299) | 13 | 350 (119, 619) | 0.026 | 8 | 63.8 (0, 167) | 14 | 361.3 (72.5, 579) | 0.055 |
| ΔEM 3 mo* | 17 | 0 (0, 167.5) | 11 | 132.5 (60, 378) | 0.129 | 8 | 6.3 (-60, 145) | 12 | 110 (1.6, 348) | 0.173 |
| 6-mo postpartum | 12 | 0 (0, 93.8) | 7 | 1030 (220, 1380) | 0.0002 | 10 | 27.5 (0, 108) | 9 | 320 (36.3, 1310) | 0.024 |
| ΔEM 6 mo* | 12 | −10 (106, 0) | 6 | 192 (-3.1, 1380) | 0.005 | 10 | −27.5 (-111, 0) | 8 | 83.1 (0, 1090) | 0.006 |
| ELISpot breadth (EB) | ||||||||||
| Third trimester | 21 | 1 (0, 1.5) | 11 | 1 (0, 4) | 0.420 | 12 | 1 (0, 1.8) | 12 | 1 (0, 4) | 0.472 |
| 3-mo postpartum | 17 | 1 (0, 2) | 13 | 4 (1.5, 6) | 0.005 | 8 | 0.5 (0, 2) | 14 | 3.5 (1, 6) | 0.044 |
| ΔEB 3 mo* | 17 | 0 (0, 1.5) | 11 | 2 (0, 2) | 0.078 | 8 | 0 (-0.8, 2) | 12 | 1 (0, 2) | 0.311 |
| 6-mo postpartum | 12 | 0 (0, 1) | 7 | 4 (3, 8) | 0.0002 | 10 | 0.5 (0, 1.3) | 9 | 3 (0.5, 7) | 0.024 |
| ΔEB 6 mo* | 12 | 0 (0, 0) | 6 | 2.5 (-0.3, 5) | 0.056 | 10 | 0 (-0.5, 0.3) | 8 | 1 (0, 3.8) | 0.121 |
| New ELISpot responses† | ||||||||||
| 3-mo postpartum | 17 | 0 (0, 2) | 11 | 2 (1, 3) | 0.025 | 8 | 0 (0, 2) | 12 | 1.5 (1, 2.8) | 0.162 |
| 6-mo postpartum | 12 | 0 (0, 0) | 6 | 2.5 (0.8, 5) | 0.002 | 10 | 0 (0, 0.3) | 8 | 1.5 (0, 3.8) | 0.047 |
| Viral genotype | ||||||||||
| 1 | 15 | 6 | 0.141 | 8 | 7 | 0.391 | ||||
| 2 or 3 | 6 | 7 | 4 | 7 | ||||||
| IFNL3 rs12979860 genotype | ||||||||||
| CC | 7 | 7 | 0.238 | 3 | 9 | 0.045 | ||||
| CT or TT | 14 | 6 | 9 | 5 | ||||||
| Mode of delivery | ||||||||||
| Cesarean | 3 | 6 | 0.057 | 2 | 6 | 0.216 | ||||
| Vaginal | 18 | 7 | 10 | 8 | ||||||
| Breastfed ever | ||||||||||
| Yes | 8 | 5 | 0.983 | 5 | 6 | 0.951 | ||||
| No | 13 | 8 | 7 | 8 | ||||||
| Breastfed ≥ 4 wk | ||||||||||
| Yes | 6 | 5 | 0.709 | 4 | 5 | 1 | ||||
| No | 15 | 8 | 8 | 9 | ||||||
Boldface entries indicate P < 0.05.
*
Δ indicates difference between third trimester and postpartum values (e.g., value3 mo postpartum – valuethird trimester).
†
Number of HCV peptide pools that had negative ELISpot responses in the third trimester and positive responses at the indicated postpartum time point.